187 related articles for article (PubMed ID: 34927457)
1. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
2. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
3. Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene.
Wu R; Li N; Wang X; Wang S; Tan J; Wang R; Zheng W
J Endocrinol Invest; 2024 Apr; ():. PubMed ID: 38662129
[TBL] [Abstract][Full Text] [Related]
4. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
[TBL] [Abstract][Full Text] [Related]
5. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
6. Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy.
Bao Y; Kim D; Cho YH; Ku CR; Yoon JS; Lee EJ
Thyroid; 2023 Nov; 33(11):1358-1367. PubMed ID: 37624749
[No Abstract] [Full Text] [Related]
7. Intestinal permeability is associated with aggravated inflammation and myofibroblast accumulation in Graves' orbitopathy: the MicroGO study.
Fenneman AC; van der Spek AH; Hartstra A; Havik S; Salonen A; de Vos WM; Soeters MR; Saeed P; Nieuwdorp M; Rampanelli E
Front Endocrinol (Lausanne); 2023; 14():1173481. PubMed ID: 38107520
[TBL] [Abstract][Full Text] [Related]
8. Practical applications of studies on the TSH receptor and TSH receptor autoantibodies.
Furmaniak J; Sanders J; Sanders P; Miller-Gallacher J; Ryder MM; Rees Smith B
Endocrine; 2020 May; 68(2):261-264. PubMed ID: 32472423
[TBL] [Abstract][Full Text] [Related]
9. The effect of acromegaly on thyroid disease.
Mo C; Zhong L
Endocr J; 2023 Nov; 70(11):1051-1060. PubMed ID: 37880078
[TBL] [Abstract][Full Text] [Related]
10. An Interesting Case of Euthyroid Graves' Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies.
Moeen Z; Aliuddin AM; Gray Wlazlo T; Majid H; Kolli S
Cureus; 2021 Oct; 13(10):e19015. PubMed ID: 34853745
[TBL] [Abstract][Full Text] [Related]
11. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
[No Abstract] [Full Text] [Related]
12. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
13. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
Singh G; Taylor B; Michalek S
Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
[TBL] [Abstract][Full Text] [Related]
14. Thyrotropin receptor autoantibody (TRAb) enhance the expression of thyrotropin receptor on mouse brain vascular endothelial cells: in vivo and in vitro.
Liang C; Yang H; Huang X; Kuang Y; Deng X; Liu Y; Luo Z
Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):67-74. PubMed ID: 37807332
[TBL] [Abstract][Full Text] [Related]
15. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
16. Comparison of orbital fibroblasts from Graves' ophthalmopathy and healthy control.
Wu Y; Zhang J; Deng W; Mo C; Liang Y; Huang K; Xu F; Tang F
Heliyon; 2024 Apr; 10(7):e28397. PubMed ID: 38571651
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab: a disease modifying treatment for graves' orbitopathy.
Ting M; Ezra DG
Thyroid Res; 2020; 13():12. PubMed ID: 32636936
[TBL] [Abstract][Full Text] [Related]
18. Association between polymorphisms in the TSHR gene and Graves' orbitopathy.
Jurecka-Lubieniecka B; Ploski R; Kula D; Szymanski K; Bednarczuk T; Ambroziak U; Hasse-Lazar K; Hyla-Klekot L; Tukiendorf A; Kolosza Z; Jarzab B
PLoS One; 2014; 9(7):e102653. PubMed ID: 25061884
[TBL] [Abstract][Full Text] [Related]
19. Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
Smith TJ
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S9-S18. PubMed ID: 38054981
[TBL] [Abstract][Full Text] [Related]
20. Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy.
Zimering MB; Shin JJ; Zaitz JD; Nunez EA; Gianoukakis AG
Endocrinol Diabetes Metab J; 2019 Feb; 3(1):. PubMed ID: 30854171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
